Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Trade Name | Waylivra |
---|---|
Common Name | Volanesorsen |
Indication | hyperlipoproteinemia type i |
Drug Class | Antisense oligonucleotides |